|
- Metastatic (stage 4) prostate cancer - Mayo Clinic
Metastatic prostate cancer diagnosis often involves blood tests and imaging tests A metastatic prostate cancer is an advanced cancer that has spread to other parts of the body This makes it a stage 4 prostate cancer A prostate-specific antigen test measures the amount of prostate-specific antigen
- METASTATIC PROSTATE CANCER HANDBOOK
Background Incorporating insights from the Association of Cancer Care Centers (ACCC) member multidisciplinary focus groups and relevant literature to spotlight barriers, this handbook offers solutions, tools, and resources for providers and patients concerning genetic testing for metastatic prostate cancer
- What to know about metastatic prostate cancer
Metastatic, or stage IV, prostate cancer is prostate cancer that has spread outside of the prostate to other parts of the body Genitourinary medical oncologist Bilal Siddiqui, M D , who treats patients with advanced prostate cancer, talks about prognosis and treatment advances
- Genetic testing for homologous recombination repair (HRR) in . . .
Patients with metastatic castration-resistant prostate cancer (mCRPC) have an average survival of only 13 months Identification of novel predictive and actionable biomarkers in the homologous recombination repair (HRR) pathway in up to a quarter of
- Treatment for Metastatic Prostate Cancer Often Suboptimal
In most people with metastatic hormone-sensitive prostate cancer, the cancer eventually changes so that it can grow without being reliant on testosterone from the testes, known as hormone-resistant (or castration-resistant) disease
- What Is Metastatic Prostate Cancer? - WebMD
Metastatic prostate cancer is an advanced form of cancer There's no cure, but you take steps to treat and control it Most people with advanced prostate cancer live a normal life for many years
- Practice Solutions for Addressing Treatment Delays in Black . . .
Medscape NewsPractice Solutions for Addressing Treatment Delays in Black Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Provided by University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL) This activity is supported by educational grants from Astellas and Pfizer Inc , Bayer HealthCare Pharmaceuticals Inc, and Janssen
- Metastatic Prostate Cancer: Updates in Management
The landscape of metastatic prostate cancer treatment is rapidly changing, with novel drugs and approaches offering promise for improved outcomes
|
|
|